Aurinia Pharmaceuticals Inc.
AUPHHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Aurinia Pharmaceuticals Inc. focuses on Biotechnology services and products. Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The $1.97B market capitalization puts AUPH squarely in small-cap range for its industry. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis.
Market Cap
$1.97B
Beta
1.45
P/E (TTM)
7.10
P/E (Fwd)
13.71
EPS (TTM)
$2.16
EPS (Fwd)
$1.12
ROE
65.0%
ROA
13.7%
Cash
$378.5M
Total Debt
$68.6M
Free CF
$124.6M
52W Change
92.6%
Annual Financials
Cash vs Debt
With $378.5M in cash and $68.6M in debt, AUPH maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow comes in at $124.6M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at 65.0%, which is exceptionally high for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Return on assets of 13.7% further supports the picture of efficient asset utilization. Revenue has grown from $134.0M (2022) to $283.1M (2025), reflecting a 111% increase over the period.
With cash comfortably exceeding debt, AUPH has financial flexibility that may help navigate uncertain periods. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing AUPH.